<DOC>
	<DOCNO>NCT01025336</DOCNO>
	<brief_summary>The purpose study evaluate level antibody 1 year receive second vaccine dose two group adult age 60 : ( 1 ) previously receive 2 dos 13-valent pneumococcal conjugate vaccine ( 13vPnC ) ( 2 ) previously receive 1 dose 13vPnc 1 dose 23-valent pneumococcal polysaccharide vaccine ( 23vPS ) . This study also assess whether use 2 vaccine , 13vPnC 23vPS , administer different sequential order result different prolong antibody level . This study limit individual participate either study 6115A1-3010 ( NCT00574548 ) 6115A1-3005 ( NCT00546572 ) .</brief_summary>
	<brief_title>Study Evaluating Persistence Of Antibody Response Elicited By 13vPnC In Healthy Adults Previously Vaccinated</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Only study volunteer receive assigned vaccination visit 1 visit 4 participate either study 6115A13010 ( NCT00574548 ) 6115A13005 ( NCT00546572 ) Vaccination license experimental pneumococcal vaccine since enrol 6115A13005 ( NCT00546572 ) 6115A13010 ( NCT00574548 ) study ( study vaccine permit 6115A13010 6115A13005 )</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Antibody persistence</keyword>
</DOC>